The RESPECT trial found that percutaneously closing a patent foramen ovale (PFO) using the Amplatzer PFO Occluder was superior to medical management in preventing recurrent ischemic stroke. Key findings showed a 45% relative risk reduction in recurrent ischemic stroke for the PFO group.
The EXCEL trial found that drug-eluting stents are a viable alternative to CABG for patients with LMCAD, with fewer MIs and less bleeding within 30 days. However, more repeat revascularization procedures were required at three years.
The Nordic-Baltic-British Left Main Revascularization Study (NOBLE) found that CABG reduced the five-year risk of MACCE compared to PCI for LMCA disease. The study demonstrated superiority of CABG over PCI in reducing non-procedural myocardial infarction and stroke.
The BIONICS trial found that the ridaforolimus-eluting stent was non-inferior to the zotarolimus-eluting stent in terms of target lesion failure rates and had a low rate of stent thrombosis. The study, which enrolled over 1,900 patients, showed similar outcomes for cardiac death, TV-MI, and ID-TLR.
The ILUMIEN III trial found that optical coherence tomography-guided PCI resulted in similar minimal stent area compared to IVUS-guidance, while also showing improved stent expansion and acute procedural success compared to angiography-guidance. Untreated major dissections were more common after IVUS-guided PCI than OCT-guided PCI.
The BIO-RESORT trial found that two thin-strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents were non-inferior to a durable polymer zotarolimus-eluting stent in treating coronary artery disease. Patients with acute coronary syndromes showed excellent one-year clinical outcomes.
Runlin Gao, MD, is being honored with the TCT Career Achievement Award for his groundbreaking work in establishing interventional cardiology in China. He has made significant contributions to the field through his research and education efforts.
The Geoffrey O. Hartzler Master Clinical Operator Award is presented to Dr. Patrick Whitlow, a renowned physician who advanced the field of interventional cardiology through his technical expertise and innovations. He was a pioneer in developing new devices and procedures for angioplasty and chronic total occlusions.
Physicians and fellows from the Cardiovascular Research Foundation will present latest data on various interventional cardiology topics, including drug-eluting stents and bioresorbable vascular scaffolds. CRF's fellowship program also supports the next generation of researchers in the field.
A study comparing OCT and IVUS guidance found that OCT-guided stents had greater in-segment percent diameter stenosis but similar major edge dissection and malapposition rates compared to IVUS-guidance. The results suggest that OCT-guidance is a viable alternative to IVUS for guiding percutaneous coronary interventions.
The BRIGHT trial demonstrated the superiority of bivalirudin over heparin monotherapy and heparin plus tirofiban in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Bivalirudin reduced bleeding rates while maintaining comparable rates of major adverse cardiac events.
A meta-analysis published in The Lancet found that longer dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with increased mortality. Shorter DAPT, on the other hand, was linked to lower rates of all-cause and non-cardiac mortality, as well as reduced risk of major bleeding.
Researchers used big data to identify crizotinib as a possible new coating for drug-eluting stents, which could reduce in-stent stenosis without affecting the endothelium. The study found that crizotinib reduced plaque buildup in blood vessels and prevented the narrowing of arteries after stenting.
The RIBS IV trial reported that everolimus-eluting stents (EES) provide superior late angiographic results and better late clinical outcomes compared to drug-eluting balloons (DEB). EES demonstrated a larger in-segment minimal lumen diameter at nine months and higher rates of freedom from target lesion revascularization.
A new study compared the effectiveness of fractional flow reserve (FFR)-guided and angiography-guided provisional side branch stenting in patients with true coronary bifurcation lesions. The FFR-guided approach yielded similar one-year composite rates of major adverse cardiac events to the current standard of care.
A randomized trial found that IVUS-guidance significantly improved 12-month clinical outcomes after new-generation drug-eluting stent implantation, compared to conventional angiography-guided CTO intervention. The IVUS-CTO study showed lower rates of cardiac death, myocardial infarction, and target-vessel revascularization in the IVUS-...
A new randomized trial demonstrated that optical coherence tomography (OCT) guidance during stent implantation in primary PCI for ST-elevation myocardial infarction (STEMI) improves patient outcomes. The OCT STEMI trial found lower area stenosis and fewer uncovered struts after nine months, indicating better long-term results.
The US CoreValve High Risk Trial found that transcatheter aortic valve replacement (TAVR) provided lower 12-month mortality compared to surgical aortic valve replacement (SAVR) in high-risk patients. TAVR also showed significant improvements in quality of life, with estimated gains of 0.24 life years and 0.20 quality-adjusted life years.
The CoreValve US Pivotal trial showed improved survival benefit in patients with aortic stenosis, with low rates of all-cause mortality and major stroke after two years. The study demonstrated durable improvement in hemodynamic valve performance and low rates of moderate or severe aortic insufficiency.
The PARTNER I trial found that TAVR demonstrated persistent mortality benefits and improved functional status after five years compared to standard therapy. This is the first long-term analysis of the randomized PARTNER I trial, which initially showed TAVR as an accepted therapy for inoperable patients with severe aortic stenosis.
Marie Claude Morice, a world-renowned interventional cardiologist, has been recognized with the Master Clinical Operator Award at TCT for her technical expertise and innovative contributions to the field of interventional cardiology. Her extensive research and clinical experience have led to significant advancements in the treatment of...
The CLEAN-TAVI trial found that using a cerebral protection device during TAVR significantly reduced the number and volume of cerebral lesions in high-risk patients with severe aortic stenosis. The study showed improved outcomes at two and seven days post-procedure.
The ISAR-CLOSURE trial reported that vascular closure devices (VCD) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. VCDs were found to reduce time-to-hemostasis, but had a higher rate of repeat manual compressions.
Dr. Mack, the first surgeon to receive the award, has made significant contributions to research involving minimally invasive surgery and percutaneous heart valve therapy. He has performed over 7,000 cardiac surgeries, including 3,000 heart valve procedures.
The first patient has been enrolled in the PROSPECT II clinical trial, a study that aims to assess the ability of intracoronary near infrared spectroscopy (NIRS) to identify non-flow obstructing vulnerable plaques. The trial will enroll 900 patients with acute coronary syndrome and follow them for up to 15 years.
The CHAMPION PHOENIX trial found cangrelor significantly reduces stent thrombosis (ST) at 48 hours and 30 days, associated with lower mortality. Cangrelor also improves freedom from ST at 30 days in various categories of ST.
A new trial found that routine availability of platelet function testing had a modest impact on selecting and dosing anti-clotting therapy. However, no significant effect was observed on major adverse cardiac events or bleeding complications.
A new trial found that patients who have no major cardiac events in the first year following coronary stenting may not require extended dual antiplatelet therapy, reducing the risk of bleeding complications. The study suggests a potential shift towards shorter treatment durations for this group of patients.
The GIANT trial found that identifying slow responders to clopidogrel through genetic profiling and adjusting treatment leads to reduced adverse events and similar ischemic event rates compared to those with a favorable genetic profile. This suggests alternative treatment strategies for patients identified as CYP2C19 poor metabolizers.
The REPRISE II trial demonstrated low rates of complications with the second-generation transcatheter aortic valve, including minimal post-procedure paravalvular aortic regurgitation. The device successfully addressed challenges associated with TAVR, improving outcomes for patients with severe aortic stenosis.
The HYBRID trial found that combining minimally invasive CABG with percutaneous coronary intervention is feasible and safe for patients with multi-vessel disease. At one year, 89.8% of the hybrid group was free from major adverse cardiac events.
A recent study of diabetic patients who underwent revascularization for multi-vessel coronary artery disease found that insulin-treated patients experienced higher rates of major adverse cardiovascular events, including death, stroke, and myocardial infarction. CABG was found to reduce mortality and myocardial infarction rates compared...
The DUTCH PEERS (TWENTE II) trial found that two third-generation permanent polymer-based drug-eluting stents had low rates of adverse clinical events, establishing the non-inferiority of a zotarolimus-eluting stent. The study also showed no significant differences in individual components of the primary endpoint.
The OPTIMIZE trial found that shortening dual antiplatelet therapy after drug-eluting stent implantation may reduce bleeding risks and treatment costs. Patients who received shorter-term therapy had similar rates of NACCE as those on longer-term therapy.
The TATORT-NSTEMI trial found that aspirating blood clots does not significantly reduce microvascular obstruction or the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI). Standard PCI without thrombectomy was shown to be equally effective.
The EUROMAX trial reveals that administering bivalirudin to STEMI patients in pre-hospital settings significantly reduces death and major bleeding complications compared to heparin. Bivalirudin also showed a lower rate of reinfarction and death, however with increased risk of acute stent thrombosis.
The CHILL-MI trial found that therapeutic hypothermia using intravenous cold saline and endovascular venous cooling reduced clinical heart failure incidence by 71% in STEMI patients. However, the trial missed its primary endpoint of reducing infarct size.
A new clinical trial found that a two-stent technique for treating bifurcation lesions with a large stenotic side branch is not associated with improved mid-term outcomes compared to a provisional stenting approach. The study, presented at TCT 2013, showed similar rates of major adverse cardiac events (MACE) between the two techniques.
The RIBS V trial found that both drug-eluting balloons and stents provide excellent long-term clinical outcomes for patients with bare metal stent restenosis. Angiographic results showed superior late angiographic results for drug-eluting stents, but low rates of clinical and angiographic recurrences in both groups.
The LEVANT 2 trial presents favorable 6-month data on drug-coated balloon angioplasty for treating femoropopliteal artery disease. Patients treated with a drug-coated balloon experienced higher primary patency rates (92.3%) compared to those receiving standard PTA alone.
The TRYTON trial compared a new bare metal bifurcation stent with standard practice and found it safe, but did not meet the non-inferiority endpoint. The strategy showed improved angiographic outcomes in larger side branches, but more frequent peri-procedural CK-MB elevations.
The SMART-CASE trial found that a conservative approach to revascularization for patients with intermediate coronary lesions is safe and comparable to an aggressive strategy. After one year, both groups had similar rates of adverse events and clinical outcomes.
The ADVISE II trial found that iFR accurately classified 94.2% of coronary stenoses, with high positive and negative predictive values for hemodynamically severe stenosis detection. The study supports the use of iFR to simplify physiological guidance of percutaneous coronary intervention without adenosine administration.
The COREVALVE EXTREME RISK trial found that the self-expanding transcatheter aortic valve reduced all-cause mortality or major stroke rate by 68% at 12 months compared to the pre-specified performance goal. The study included 487 patients with severe aortic stenosis, most of whom were elderly and had high surgical risk.
The SAFE-PCI for Women trial found that radial access reduced bleeding and complication rates compared to femoral access, with a significant benefit seen in the overall cohort. The study's findings suggest that radial access is a reasonable strategy for women undergoing cardiac catheterization.
The SORT-OUT VI trial found that both zotarolimus-eluting and biolimus-eluting stents were associated with low major adverse cardiac events. The study demonstrated the non-inferiority of biocompatible polymer stents compared to biodegradable polymer-coated stents in patients undergoing percutaneous coronary intervention.
The PROSPECT II trial will enroll 900 patients with acute coronary syndrome to assess the ability of intracoronary near infrared spectroscopy (NIRS) to identify non-flow obstructing vulnerable plaques. The study will also evaluate the feasibility of a bioresorbable scaffold in preventing future major adverse cardiovascular events.
High platelet reactivity after drug-eluting stent implantation was associated with increased risk of stent thrombosis and heart attack, while also reducing major bleeding. However, the association between high platelet reactivity and mortality was not independent.
In a study of patients over 80, drug-eluting stents demonstrated lower rates of target vessel revascularization and myocardial infarction compared to bare-metal stents. The XIMA trial found that both types of stents offered good clinical results in this age group.
Renu Virmani received the 2012 TCT Career Achievement Award for her groundbreaking contributions to interventional cardiovascular medicine. The award honors a pioneer in the field of transcatheter cardiovascular therapies.